Follow Us GraphicFacebook IconTwitter IconLinkedIn Icon
Search Graphic

Expert Financial Analysis and Reporting

Tag archive for ‘Prophage G-100’

Agenus: Rebuttal To Attack By Adam Feuerstein on the Company (AGEN, Buy, $2.85)

Report Overview Adam Feuerstein launched a withering attack on Agenus (AGEN) and me in his column. The gist of the article is that Agenus is misrepresenting data pertaining to the use of Prophage in glioblastoma in ways that overstate Prophage’s efficacy and I am naively buying into this. It was a very short note on […]

Agenus: Thoughts on Phase II Results for Prophage in Glioblastoma (AGEN, $2.91)

Reason for This Report Agenus (AGEN) just issued an update on a phase II trial of Prophage G-100 combined with current standard of care in newly diagnosed glioblastoma patients that showed median overall survival (OS) of 23.3 months. There was no control group in the study but data from recent trials suggests that OS with […]